Calcium-activator protein for secretion (CAPS) is a cytosolic protein that associates with large dense-core vesicles and is involved in their secretion. Mammals express two CAPS isoforms, which share a similar domain structure including a Munc13 homology domain that is believed to be involved in the priming of secretory vesicles. A variety of studies designed to perturb CAPS function indicate t...

Abstract. In the projective space PG(3, q) with odd prime q ≡ 2 (mod 3), q ≥ 11, a new infinite family of complete (q + q + 8)/2-caps is constructed. It gives a new lower bound on the second largest size m′2(3, q) of complete caps: (q 2 + q + 8)/2 ≤ m ′2(3, q). The structure of one of the two existing complete 20-caps in PG(3, 5) is described. The new upper bounds on the smallest size of comple...

Objective Cryopyrin-associated periodic syndrome (CAPS) is a heterogeneous group of diseases characterized by excessive Interleukin-1b (IL-1 b) release resulting in severe systemic and organ inflammation. Canakinumab targets IL-1b and is approved at standard dose for children and adults with all CAPS phenotypes. Limited data are available regarding real-life effectiveness of canakinumab in pati...

Introduction Cryopyrin-associated periodic syndrome (CAPS) is a constellation of diseases with a different and varying clinical spectrum which is rarely seen in childhood. The mildest form of CAPS which is familial autoinflammatory syndrome and the most severe form which is chronic inflammatory neurologic cutaneous arthropathy (CINCA) possess a very different spectrum of clinical findings. Most...

Neuropeptide and peptide hormone secretion from neural and endocrine cells occurs by Ca(2+)-triggered dense-core vesicle exocytosis. The membrane fusion machinery consisting of vesicle and plasma membrane SNARE proteins needs to be assembled for Ca(2+)-triggered vesicle exocytosis. The related Munc13 and CAPS/UNC31 proteins that prime vesicle exocytosis are proposed to promote SNARE complex ass...

Introduction Interleukin-1b (IL-1b) is a basic mediator of cryopyrinassociated periodic syndromes (CAPS). In this respect an experience of the use of IL-1 inhibitors has been gained in patients with CAPS. Canakinumab was approved by FDA and EMEA in 2009 and registered in the Russian Federation in 2011 for treatment of CAPS. Canakinumab is shown to have high efficiency and good tolerability in p...

BACKGROUND Medicaid programs face growing pressure to control spending. Despite evidence of clinical harms, states continue to impose policies limiting the number of reimbursable prescriptions (caps). We examined the recent use of prescription caps by Medicaid programs and the impact of policy implementation on prescription utilization. METHODS We identified Medicaid cap policies from 2001-20...

This qualitative research aimed to investigate the social life of patients with a diagnosis of schizophrenia at a Psychosocial Care Center (CAPS), and identify how the therapeutic process offered by the CAPS has contributed to their social lives. The subjects of the study were patients with schizophrenia, between eighteen and forty years of age and registered at the CAPS in Uberaba, Brazil. The...